Published in Hepatitis Weekly, February 4th, 2002
A research team in Japan recently attempted to answer that question by analyzing several patients given standard regimens of IFN-(beta), but their analysis left many questions unanswered.
In the study, 109 chronic hepatitis C patients received 6 MU doses of IFN-(beta) daily for up to 12 weeks. "When serum ALT levels during the therapy were higher than three times the level before the therapy, liver biopsy was...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.